Efficacy and safety of human umbilical cord-derived mesenchymal stem cells for COVID-19 pneumonia: a meta-analysis of randomized controlled trials

Table 1 Characteristics of included studies

	Author	Country	Study type	Patient number			Mean age			Female sex (%)			F/U	Outcomes
				Total	MSC	Ctrl	Total	MSC	Ctrl	Total	MSC	Ctrl
2021	Zhu et al.	China	phase II RCT	58	29	29	63.49	62.04	64.93	62.1	58.60	65.5	4W	mortality, AE, CRP
2020	Shu et al.	China	RCT	41	12	29	58.78	61	57.86	41.46	33.33	44.83	4W	mortality, CRP, IL-6
2021	Shi et al.	China	phase 2 RCT	100	65	35	60.45	60.72	59.94	44	43.08	45.71	4W	mortality, AE, SAE, IL-6, IFN-γ
2022	Monsel et al.	France	phase 2b RCT	45	21	24	63.57	64.00	63.20	17.78	19.05	16.67	4W	mortality, AE, SAE
2021	Lanzoni et al.	America	phase 1/2a RCT	24	12	12	59	58.58	58.83	45.8	58.30	33.3	1 M	mortality, AE, SAE, IL-6, IFN-γ
2021	Dilogo et al.	Indonesia	RCT	40	20	20	NR	NA	NA	25	25	25	1 M	mortality, AE, SAE
2021	Adas et al.	Turkey	RCT	20	10	10	NA	NR	NR	NA	NR	NR	3 M	mortality, AE, SAE, CRP, IL-6, IFN-γ

MSCs, mesenchymal stem/stromal cells Ctrl; RCT, Randomized controlled trial; AE, adverse event; SAE, Serious adverse event; CRP, C-reaction protein; IL-6, Interleukin-6; IFN-γ, Interferon-gamma; F/U, follow-up; W, week; M, month

ISSN: 1757-6512